drug hunter

2023 Novel Small Molecule FDA Drug Approvals Full article, high-resolution PDF, and more details: drughunters.com/4aS31en

Despite progress in prevention and treatment, HIV remains a global epidemic, impacting nearly 40 million people worldwide in 2023. Merck is currently developing MK-8527, a novel oral NRTTI (nucleoside reverse transcriptase translocation inhibitor) designed for long-acting,…

First Disclosure of Proposed Drug Names (and Structures): INN List 133 | drughunters.com/4m5JhZE The INN (International Nonproprietary Names) Proposed List 133, released in July, 2025, unveils the latest batch of drug names currently under consideration by the WHO. To…

The Evolution of SGLT2 Inhibitors: From Apple Tree Bark to Clinical Impacts Beyond Glycemic Control | drughunters.com/3H2kuXq The global epidemic of obesity and T2DM continues to grow at an alarming pace. In the United States alone, more than 38 million—nearly 1 in 10…

Glucokinase Target Brief | drughunters.com/3TVn70c Glucokinase is an example of a “hot” T2DM drug target with a promise that remains unfulfilled. Although the GK activator dorzagliatin has been approved for treatment of T2DM in China, questions remain about its long term…

Molecules of the Month – June 2025 | drughunters.com/4eZgDH8 Drug Hunter’s June Molecules of the Month highlight Bayer's sevabertinib, an oral mutant HER2-targeted TKI under FDA Priority Review for previously treated HER2-mutant nSCLC, and onradivir, an Influenza PB2 inhibitor…

Key Clinical Updates from June 2025 | drughunters.com/4m5YQAD In our recap of the clinical news from June 2025, we highlight the FDA approval of Gilead’s twice-yearly shot for HIV prevention and Nuvation Bio's ROS1 inhibitor for non-small cell lung cancer. Our article also…

Sebetralstat Marks the First Oral and On-Demand Plasma Kallikrein Inhibitor Approval | drughunters.com/46NvsdK KalVista’s plasma kallikrein inhibitor sebetralstat, has been approved as the first and only oral on-demand treatment for HAE (hereditary angioedema). HAE…

📣 Reminder Not a Hypothesis: The Free Drug Principle drughunters.com/4kBN4MZ Thursday, July 24th, 2025 8 AM PT / 11 AM ET / 5 PM CET Join us for a thought-provoking Flash Talk with Dennis Smith, Drug Discovery Executive and former Vice President at Pfizer who will clarify…

Small Molecules Unlock Big Opportunities in GLP-1R Drug Development | drughunters.com/3UnBwlL GLP-1R agonists have already transformed diabetes and obesity treatment—and are now being investigated in everything from addiction to neurodegenerative disease. While injectable…

We had a fantastic time reconnecting with familiar faces and welcoming new ones at our recent mixer in San Francisco! A highlight of the evening was sharing Drug Hunter’s 2024 Molecules of the Year — with half of the nominated molecules having ties to the Bay Area. A perfect…

Big Money Bets from June 2025 | drughunters.com/3It3Bpj In our June recap of biopharma deals, we highlight Sanofi acquiring Blueprint for $9.1B, Novo Nordisk partnering with Deep Apple Therapeutics on small molecule obesity drugs, BMS paying Philochem for a radiolabeled ACP3…

Multi-functional ADCs for Cancer Therapy - FACT or FICTION?drughunters.com/4lZespx Thursday, August 14th, 2025 8 AM PT / 11 AM ET / 5 PM CET Since the approval of the first ADC gemtuzumab ozogamicin in 2000, these precision medicines became available as treatment options in…

Can Brensocatib Open the Door for Neutrophil-Modulating Drugs? | drughunters.com/3ItDcb2 Brensocatib is an oral, reversible covalent, small molecule inhibitor of DPP1, currently under priority review by the FDA for the treatment of non-cystic fibrosis bronchiectasis—a severe,…

How to Use Drug Hunter to Improve Design Ideas Tuesday, July 22nd, 2025 8 AM PT | 11 AM ET | 5 PM CET One of the most common questions during the design process for new drug molecules is whether a particular structural motif appears in FDA-approved drugs or recent clinical…

BBO-10203, A Potential First-in-Class PI3Kα:RAS Protein-Protein Interaction Inhibitor Advances to Phase I Trials | drughunters.com/4ksBKTl BBO-10203 is a potential first-in-class covalent inhibitor of the PI3Kα:RAS interaction, a critical oncogenic signaling pathway. BBO-10203…

JNJ-6640 Reveals Purine Deprivation Strategy Against Drug-Resistant TB | drughunters.com/4eCuvXA JNJ-6640, recently reported by a consortium led by Janssen in collaboration with the University of Cape Town and the London School of Hygiene and Tropical Medicine, is a novel…

IRF5 Target Review: Highlighting Two Divergent Approaches to an "Undruggable" Transcription Factor | drughunters.com/4ktbY1l Successful drugging of transcription factors remains a significant challenge within drug discovery. These proteins are notorious for lacking “classically”…

Not a Hypothesis: The Free Drug Principle drughunters.com/45Z4y2h Thursday, July 24th, 2025 8 AM PT / 11 AM ET / 5 PM CET The free drug principle is fundamental to interpreting PK data, conducting PK/PD modeling, and optimizing drug candidates, but it is often misunderstood in…

Janssen’s seltorexant (JNJ-42847922) is a selective OX2R antagonist designed to treat MDD (major depressive disorder) in patients who also experience insomnia symptoms—a patient population with limited targeted options. Read the full Drug Hunter article to explore the molecule’s…

No Fast Track for Myosin Inhibitor Sevasemten: Edgewise Seeking Ph. 3 Clinical Trial | drughunters.com/45S5N3f Sevasemten, an oral myosin ATPase inhibitor, is currently in Ph. 2 trials for both Becker (BMD) and Duchenne muscular dystrophy (DMD). While the FDA recently declined…